Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neovasc Plans Next Steps After Thumbs Down From FDA Panel

Executive Summary

FDA advisory committee members said the trial population was too small and homogenous and did not establish that Neovasc’s Reducer effectively treats angina.

You may also be interested in...



FDA Schedules Advisory Panel To Review Neovasc’s Angina Treatment

The US FDA's Circulatory System Devices Panel will meet on 27 October to evaluate Neovasc’s Reducer device, a minimally invasive treatment for drug-refractory angina.

COVID-19 Serology Templates: FDA Updates Sponsor Template, Adds Home Test Document

The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.

Hologic Aptima Assay Cleared For HIV Detection

Already cleared to monitor the viral load in HIV-positive individuals, the test has now been approved for initial diagnosis as well.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel